Journal
RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS
Volume 5, Issue 4, Pages -Publisher
WILEY
DOI: 10.1002/rth2.12512
Keywords
direct oral anticoagulants; DOAC; embryotoxicity; heavy menstrual bleeding; HMB; pregnancy
Categories
Ask authors/readers for more resources
DOACs are increasingly used as a replacement for traditional anticoagulants due to advantages such as fewer drug interactions and fixed dosing. However, special considerations, such as heavy menstrual bleeding and embryotoxicity risk during pregnancy, may need to be taken into account for younger female patients receiving DOAC therapy.
Direct oral anticoagulants (DOACs) are replacing warfarin and other vitamin K antagonists for a wide range of indications. Advantages of DOAC therapy are fewer food and drug interactions and fixed dosing without routine laboratory monitoring, making DOACs the perfect choice especially for younger patients, in whom the main indication for anticoagulation is prevention and treatment of venous thromboembolism (VTE). Although DOACs are safer and much more convenient than other anticoagulant alternatives, their profile may have drawbacks, especially for younger female patients in whom reproductive issues need special considerations. These may include the issue of heavy menstrual bleeding (HMB) during anticoagulant therapy, the embryotoxicity risk from inadvertent DOAC exposure during pregnancy, and the prevention or planning of pregnancies during DOAC therapy. This review summarizes the most relevant evidence in this increasingly important field of women's health.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available